Introduction {#s1}
============

The fungus *Claviceps purpurea* produces ergot alkaloids that invade cereal crops globally. In livestock feed, it is well established that the presence of high concentrations of ergot alkaloids are associated with clinical manifestations, including gangrene, abortion, stillbirth, decreased birth weight, decreased immunity, and decreased fertility in multiple animal species ([@CIT0009]). These effects are mainly related to the vasoconstrictive effects of ergot alkaloids, through structural similarity to biological amines binding to their receptor, on multiple arterial and venous vascular beds impacting the blood supply to multiple organs.

Over 90 ergot alkaloids have been isolated, which are separated into two main categories, including amide derivatives of lysergic acid and small peptides (ergopeptines), based on chemical structure ([@CIT0018]). Small peptide ergot alkaloids exist in two conformational forms known as the (*R*)-epimers and the (*S*)-epimers. The two forms are in equilibrium with the transformation of (*R*)-epimers to their respective (*S*)-epimers being complex and dependent on several factors, including temperature, pH, and solvent for experimental use. The transformation passes through an intermediate conformation. The (*R*)-epimers contain the suffix "ine" whereas the (*S*)-epimers contain the suffix "inine" ([@CIT0016]).

Both forms have been shown to have different chemical, physical, and biological properties ([@CIT0026]). It is currently thought, under normal physiological conditions, that the (*R*)-epimers exert biological effects, whereas the (*S*)-epimers are inactive ([@CIT0026]; [@CIT0010]; [@CIT0007]; [@CIT0017]). Original reports from the 1970s to 1980s are often cited in current publications stating inactiveness ([@CIT0027]; [@CIT0025]).

The bioactivity, in terms of vasoactivity, of (*R*)-epimers is commonly assessed using an in vitro tissue bath system where the contractile response of dissected arteries is monitored after incubation with increasing concentrations of a particular (*R*)-epimer (Klotz et al., 2010;[@CIT0006]; [@CIT0014]). Specifically, cattle arteries ([@CIT0023], [@CIT0013], [@CIT0006]), such as the dorsal metatarsal artery ([@CIT0023]; [@CIT0030]), have been utilized. It is hypothesized, based on a similar chemical structure, that the (*S*)-epimers of ergot alkaloids will cause arterial contraction similar to (*R*)-epimers. Therefore, the objective of this study was to examine the vasoactivity potential (contractile response) of bovine metatarsal arteries after incubation with one of four (*S*)-epimers, including ergocryptinine, ergocristinine, ergocorninine, and ergotaminine using an in vitro tissue bath system.

Materials and Methods {#s2}
=====================

No ethics approval was required. The primary investigator (A.N.A) was required to submit a form to the University Ethics Committee indicating only the number of animals to be slaughtered. Animal slaughter was performed according to slaughterhouse guidelines by slaughterhouse employees.

Animals and arteries {#s3}
--------------------

Dorsal metatarsal arteries were collected from healthy mixed-breed beef steers (*n* = 12) aged 15 to 20 mo immediately after the slaughter at a local abattoir. One foot limb, with the hide removed, was given to the researcher located in a separated space within the abattoir approximately 7 min after animal was euthanized (one foot limb collected per day). From each foot limb, muscle, nerves, and tissues were removed to access a 15-cm segment of the dorsal metatarsal artery that was located directly next to the bone. Once the segment was carefully removed using surgical scissors and a scalpel, it was placed in a small container with a lid containing modified Krebs--Henseleit oxygenated buffer, (95% oxygen/5% carbon dioxide mixture; pH = 7.4; composition in g/2 liters deionized water: 13.68 NaCl, 0.7 KCL, 0.28 MgSO~4~, 0.32 KH~2~PO~4~, 3.6 NaHCO~3~, 1.8 glucose, and CaCl~2~, made in house) and on ice for transport to the laboratory ([@CIT0014]). Upon arrival to the laboratory, excess fat and connective tissue were removed from each artery segment ([@CIT0011]), which were sliced into 3-mm arterial cross sections ([@CIT0014]). Four arterial cross sections were suspended horizontally in a four-chamber (one arterial cross section per chamber) tissue bath (Radnoti \[159906\], Monrovia, CA, USA) containing 15 mL of continuously oxygenated (95% oxygen/5% carbon dioxide) modified Krebs--Henseleit buffer, same as above, at 37 °C. Arterial cross sections were then allowed to equilibrate for 1 h with a resting tension of 2 g, with buffer solution replacement every 15 min ([@CIT0006]; [@CIT0030]). Arterial cross sections were then exposed to an alpha-adrenergic agonist, phenylephrine (**PE**) (1 × 10^--4^ M, Fisher Scientific, Fair Lawn, NJ), to verify viability and to provide contraction information to normalize experimental contractions. Arterial cross sections were then washed every 15 min with incubation buffer to restore resting tension with 4 to 6 replacements made.

Ergocristinine, ergocorninine, ergocryptine, and ergotaminine cumulative concentration--response {#s4}
------------------------------------------------------------------------------------------------

For each experimental run, two of the four arterial cross sections, from a 15-cm artery segment, would receive one (*S*)-epimer and the other two would receive a different (*S*)-epimer. Values for the contraction of each artery segment were based on the average of duplicated arterial cross sections (two (*S*)-epimers and two arterial cross sections/(*S*)-epimer). Twelve (*n* = 12) arteries (artery segments) in total were used with six (*n* = 6) exposed to ergocryptinine and ergocorninine, and the other six (*n* = 6) exposed to ergocristinine and ergotaminine (*n* = 6 arteries/(*S*)-epimer). After resting tension was restored, (*S*)-epimers were added separately to each chamber in the tissue bath from lowest concentration (1 × 10^--11^ M) to highest (1 × 10^--6^ M) for an incubation period of 29 min, with one buffer replacement, followed by a 2.5-min washout period and 1 min recovery before the next (*S*)-epimer addition ([@CIT0014], with slight modification). Preliminary investigation indicated that the arteries do not relax after the (*S*)-epimers were removed from the buffer within the tissue bath. The arteries continued to increase in contractility several minutes after the (*S*)-epimers were washed out. This is consistent with a previous study with (*R*)-epimers ([@CIT0024]). In comparison, when PE was washed out from the buffer solution, the contraction abated almost immediately. A maximal response was not achieved in a 9- or 14-min incubation period, which had been used in previous validated assays ([@CIT0012]; [@CIT0014]); therefore, a longer incubation period for each (*S*)-epimer was employed to ensure contraction was not overlooked. After the last concentration, PE (1 × 10^--4^ M) was added again to ensure viability of all arterial cross sections. Arterial cross sections exposed to PE at the conclusion of an experimental run had similar contractile responses to the first PE additions. Stock solutions of ergocristinine (Romer Labs, Vancouver, BC), ergocorninine (Romer Labs, Vancouver, BC), ergotaminine (U.S. Pharmacopeia, Rockville, MD) were prepared in 100% methanol (Fisher Scientific, Fair Lawn, NJ), and ergocorninine prepared in 100% ethyl acetate (Fisher Scientific, Fair Lawn, NJ) ([@CIT0013]) within the manufacturer amber vials, all stored at −20 °C ([@CIT0026]; [@CIT0008]). From the stock solutions, dilutions were made to obtain the desired concentrations, the day of the experimental run, while arterial cross sections were equilibrating. Each concentration of the working standards was made within a 1.5-mL microcentrifuge tube with a snap cap (Labcon North America, Petaluma, CA) and stored in dark and on ice within a coved styrofoam container until use. The volume of solvent used for each concentration of (*S*)-epimer did not exceed 0.5% of the 15 mL buffer within the tissue bath.

Data collection and statistical analysis {#s5}
----------------------------------------

Contractile responses of each arterial cross section exposed to PE or tested (*S*)-epimers were recorded as grams of tension using Biopac Student Lab PRO (professional version 3.7.1, Goleta, CA), which was connected to the four-chamber tissue bath. At the end of the 29-min incubation period of each (*S*)-epimer, grams of tension were recorded and corrected to the baseline tension. The baseline tension was calculated from average tension prior to the demonstration of contraction (increased tension) to ensure that the natural resting baseline tension of each arterial cross section was not missed. These values were then normalized as a percent of the first addition of PE (1 × 10^--4^ M) to compensate for the variability of animals as well as artery size. These data were used as a source for data analysis. All data were reported as mean ± SD, with contractile response expressed as a percent of PE contraction for each (*S*)-epimer. Data were plotted with nonlinear regression using GraphPad Prism version 8.0.0 (GraphPad Software, San Diego, CA).

All analyses were performed using a commercial software package (IBM SPSS Statistics for Windows, version 23, IBM Corp., Armonk, NY). Statistical tests evaluated if mean % contractile response of PE for bovine arterial segments was affected by the two variables, epimer ((*S*)-epimers of four alkaloids) and concentration, when considered together. The (*S*)-epimers were ergotaminine, ergocristinine, ergocorninine, and ergocryptinine; *n* = 6, ergocryptinine and ergocorninine; *n* = 6, ergocristinine and ergotaminine (*n* = 6 arteries/(*S*)-epimer, total of *n* = 12 arteries). Data were included for each concentration where a contraction was observed (1 × 10^--7^ and 1 × 10^--6^ M). Statistical analysis was undertaken using generalized estimating equations (**GEE**) with an identity link function, robust errors, and an unstructured correlation matrix to account for repeated measures (segments of the same artery measured at different concentrations and for different (*S*)-epimers). GEE is able to correctly analyze results from an unbalanced design with incomplete repeated measures (each steer artery did not receive all (*S*)-epimers). Differences were considered to be significant at *P* \< 0.05. In the presence of a significant interaction effect between (*S*)-epimer type and concentration on the percent contractility, GEE analysis was performed separately at each individual concentration to test whether a difference in effect existed between (*S*)-epimers. This was followed by multiple pairwise comparisons with a sequential Sidak correction. To test if arterial contraction from each (*S*)-epimer/concentration combination was different from zero, an individual one-sample *t*-test was utilized.

Results {#s6}
=======

All four (*S*)-epimers caused a measurable contraction of bovine dorsal metatarsal arteries at a concentration of 1 × 10^--7^ M. The arterial contractile response increased at the next highest concentration of 1 × 10^--6^ M ([Figure 1](#F1){ref-type="fig"}). Of the four (*S*)-epimers, at the highest concentration, ergotaminine generated the strongest contraction of followed by ergocorninine, ergocristinine, and ergocryptinine. This study demonstrated a statistically significant interaction effect between (*S*)-epimer type and concentration on the percent contractility (*P* \< 0.001). Due to a significant interaction, GEE analysis was performed separately at each individual concentration to test whether a difference in effect existed between (*S*)-epimers (*P* \< 0.001 for each concentration). Specifically, at 1 × 10^−7^ M, ergocryptinine resulted in a lower percentile contraction to ergotaminine (*P* = 0.011). At 1 × 10^--6^ M, ergocryptinine and ergocristinine each resulted in a significantly lower percentile contraction than ergotaminine (*P* = 0.011 and *P* = 0.001, respectively) ([Table 1](#T1){ref-type="table"}). The arterial contraction from each (*S*)-epimer/concentration combination was different from zero (*P* \< 0.05), with the exception of both ergocryptinine and ergocorninine at 1 × 10^−7^ M. The addition of PE at the conclusion of the experiment resulted in a large increase in contraction similar to the first PE addition.

![Contraction of bovine arteries from (S)-epimers. Mean contractile response, % of first addition of PE, of bovine metatarsal arteries to increasing concentrations of (S)-epimers, namely ergocryptinine, ergocristinine, ergocorninine, and ergotaminine (*n* = 6, ergocryptinine and ergocorninine; *n* = 6, ergocristinine and ergotaminine; *n* = 6 arteries/(S)-epimer, total *n* = 12). Error bars are SD.](skaa203f0001){#F1}

###### 

Comparison of mean arterial contractile responses to increasing concentration of four (S)-epimers of ergot alkaloids, namely ergotaminine, ergocorninine, ergocristinine, and ergocryptinine after normalization to PE at two concentrations where contraction was observed

                   Concentration (1 × 10^x^), M   Contraction, g as % PE contraction, Mean ± SD   Min.^1^   Max.^2^
  ---------------- ------------------------------ ----------------------------------------------- --------- ---------
  Ergotaminine     −7                             3.90 ± 2.80^a^                                  1.04      8.78
                   −6                             17.39 ± 4.64^c^                                 10.06     22.44
  Ergocorninine    −7                             1.64 ± 2.21^a,b^                                −0.55     5.57
                   −6                             10.85 ± 9.35^c,d^                               0.00      27.87
  Ergocristinine   −7                             2.24 ± 1.94^a,b^                                0.44      5.63
                   −6                             7.98 ± 2.71^d^                                  4.01      12.13
  Ergocryptinine   −7                             0.49 ± 0.91^b^                                  −0.02     2.06
                   −6                             7.69 ± 7.10^d^                                  −1.71     18.62

^1^Minimum arterial contractile response, % contractile response of PE.

^2^Maximum arterial contractile response, % contractile response of PE.

^a--d^(*S*)-epimers demonstrating significant differences between contraction of bovine arteries are designated by different letters at 10^−7^ M (a,b) and 10^−6^ M (c,d) (*n* = 6 arteries/(*S*)-epimer, total *n* = 12, GEE, multiple pairwise comparison with Sidak correction, *P* \< 0.05).

Discussion {#s7}
==========

The bovine metatarsal artery was selected due to its peripheral location within the limb and potential for clinical disease (lameness). The presence of a contractile response of bovine metatarsal arteries exposed to increasing concentrations of (*S*)-epimers, namely ergotaminine, ergocorninine, ergocristinine, and ergocryptinine, illustrates vasoactivity and the potential for vasoconstriction leading to toxic effects. The findings of the present study demonstrate the biological activity of (*S*)-epimers, which have been previously stated as inactive ([@CIT0026]; [@CIT0010]; [@CIT0007]; [@CIT0017]). Evidence from previous studies have implied that the (*S*)-epimers may be toxic due to accumulation within cell lysate ([@CIT0020]; [@CIT0022]), although stating that more research need to be completed, especially on single epimers. It has been reported that (*S*)-epimers negatively affected the blood--brain barrier ([@CIT0021]), which also supports (*S*)-epimers having biological activity, due to not only accumulation but also perhaps receptor activation as seen in the present study.

Few studies examined the contractile response of (*R*)-epimers in bovine metatarsal arteries to provide published comparators for the present study. In a previous study examining the contractile response of (*R*)-epimers using a bovine ruminal artery, the contractile response of ergotamine was first observed at 10^−6^ M, while ergocornine and ergocryptine did not cause contraction until the 10^−5^ M addition and only the highest dose of ergocristine (10^−4^ M) elicited a contractile response ([@CIT0006]). Two other in vitro studies reported an arterial contractile response for lysergamide and ergovaline using bovine metatarsal and uterine arteries, respectively. Lysergamide first elicited a contractile response at 10^−7^ M, while ergovaline resulted in slow but sustained contractions over 2 h suggesting a high affinity to the receptors ([@CIT0005]; [@CIT0023]). Comparing results in the present study to previous investigations indicate that the (*S*)-epimers may be more potent than their corresponding (*R*)-epimers. The contractile response seen in the present study at the two concentrations, 10^−7^ and 10^−6^ M, was visually similar to graphed results provided for similar-sized arteries exposed to (*R*)-epimers ([@CIT0013]; [@CIT0014]). The difference/similarity, however, could be related to the use of various arterial segments and experimental differences in the studies mentioned. It is anticipated that incubation with higher concentrations of the (*S*)-epimers would generate similar higher comparable contractile responses as demonstrated in other studies using the corresponding (*R*)-epimers.

It is important to note that the current study was conducted using only the lower end of the concentration range than what is commonly used for the (*R*)-epimers studies (1 × 10^−9^ to 1 × 10^−4^ M; [@CIT0014]). The (*S*)-epimers are available commercially from few sources and only in very limited quantities (0.125 mg/vial). To achieve concentrations exceeding 1 × 10^−6^ M of an (*S*)-epimer within a single tissue bath was practically unrealistic. Also, a measurement of potency such as the effective concentration giving half-maximal response (**EC50**) is commonly used in in vitro arterial tissue bath studies ([@CIT0023]; [@CIT0013]). However, it was not appropriate to include EC50 values in the present study because arterial contraction was observed at only two concentrations. A reliable EC50 value requires multiple data points to be useful. Kinetic modeling would not have generated reliable results for this descriptive study.

To the authors' knowledge, no studies have been performed to assess the contractile activity of the (*S*)-epimers or the contractile response resulting from the transformation of (*R*)-epimers to (*S*)-epimers. To assess the contractile response in vascular beds, dissected arteries or veins must be maintained alive under normal physiological conditions of pH (7.4), temperature (37 °C), nutrients, and gas. Under these experimental conditions, it is possible for the transformation between the (*R*) and (*S*)-epimers to occur until an equilibrium is reached ([@CIT0015]; [@CIT0026]). We, therefore, cannot rule out the possibility that the contractile response seen in the present study was, in part, due to the transformation of the (S)-epimer to the (*R*)-epimer. However, this transformation was unlikely. The reason being, the transformation of the (*S*) to (*R*)-epimer is not favored and the (*S*)-epimer slightly dominates the equilibrium ([@CIT0001]). The (*S*)-epimer would have to undergo a more difficult rearrangement to switch to the intermediate and, therefore, the (*R*)-epimer. This is also supported by examining the transformation of a (*R*)- to (*S*)-epimer under physiological conditions ([@CIT0026]). When an aqueous solution was used to assess the epimerization of pure ergovaline (*R*) at 37 °C (pH 7.5), equilibrium was reached after 11 h and only 59.4% of ergovaline (*R*) remained. The transformation between epimers has been observed at 75 min ([@CIT0026]), which is longer than the time period used in the present study. At the highest concentration used, for specific (*S*)-epimers, there was observation of slight artery contraction within 14 min of incubation and an increase in contraction at the end of the 29-min incubation period. Analytical detection of each form of epimer in the buffer solution may provide evidence for which form is present and/or dominant. However, the time and methods needed for testing will likely result in an increase in epimer transformation. This will not accurately reflect the conformational form of an epimer at the time of artery contraction. Therefore, the time frame within the present experiment, along with the likeliness of the transformation of ergot alkaloids favoring the (*S*)-epimers within the conditions used, pH 7.5 and 37 °C, it is strongly suggested that the (*S*)-epimer administered to the buffer within the tissue bath did not transform into the (*R*)-epimer. This supports that the S-epimers were responsible for the arterial contraction observed.

The (*R*) and (*S*)-epimers of ergot alkaloids are found in almost all food products derived from *Claviceps*-infested crops. Along with animal feed, food products intended for human consumption (including, but not limited to, baby formula, bread, and pasta) may contain ergot (*S*)-epimers ([@CIT0004]). Studies often report that the "harmful" (*R*)-epimers convert to the "inactive" (*S*)-epimers after food processing intended for human consumption ([@CIT0019]). One study examined changes in concentrations of six (*R*)- and (*S*)-epimers during the production of rye bread ([@CIT0002]). The study reported that thermal processing (or baking) caused the concentration of the (*R*)-epimers to decrease but resulted in an increase of (*S*)-epimers. The study concluded that baking contributes to the reduction of toxicity of the final bread product. Similarly, a study examining the milling of durum and the production of pasta reported comparable results ([@CIT0029]). These studies emphasize the importance of understanding specifically the biological effect of (*S*)-epimers and the significance of the findings in the present study.

The (*S*)-epimers used in the present study are routinely encountered in cereal crops in Western Canada ([@CIT0028]). The mere presence of a contractile response after incubating arteries with four different (*S*)-epimers indicates that their presence in human diets and animal feed may be significant and should be considered in analytical and food safety assessments. Concentrations of (*R*)-epimers are monitored in human and animal feed worldwide by regulatory agencies in many countries, whereas (*S*)-epimers are not measured or evaluated in human and animal feed standards in North America ([@CIT0003]). Since the (*S*)-epimers are thought to be biologically inactive, their concentrations in the feed are considered less important. Previously, studies report that the quantification of (*R*)-epimers should consider their epimerization toward (*S*)-epimers and, therefore, utilize extraction solvents and conditions that decrease the chance of epimerization ([@CIT0026]). However, because these conditions are not easy to maintain in an experimental setting and naturally contaminated feed contain (*R*)- and (*S*)-epimers, it is important to quantify both ([@CIT0007]). The adverse manifestations such as ergotism seen in livestock, as a result of contaminated feed consumption, are likely produced by the combined action of the (*R*)- and (*S*)-epimers and not exclusively the (*R*)-epimers.

In conclusion, this study reports the demonstration of biological activity for four (*S*)-epimers of ergot alkaloids, namely ergotaminine, ergocorninine, ergocristinine, and ergocryptinine, through potential vasoconstriction as demonstrated by arterial contraction, which were thought to be previously inactive. Ergotaminine had the greatest contractile response compared with the other (*S*)-epimers with each having different degrees of contractility. This may be similar to that reported for (*R*)-epimers ([@CIT0013]). Future work would include the comparison of contractility between (*R*) vs. (*S*)-epimers. This will be beneficial for understanding the potencies of each form. The mere presence of a contractile response in bovine arteries stimulates future discussion concerning the biological activity of (*S*)-epimers in multiple settings, which may influence the direction of, and development of, regulatory standards for ergot concentrations relating to human and animal food safety worldwide.
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